ACCESS Newswire

Jupiter Wellness, Inc.

Share
Jupiter Wellness Announces Appointment of Dr. Andy Goren to Scientific Advisory Board

JUPITER, FL / ACCESSWIRE / July 15, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today announced that Dr Andy Goren has been appointed to its Scientific Advisory Board.

Dr. Andy Goren has more than twenty years of experience in clinical research, development, and commercialization of breakthrough therapeutics and diagnostics. Among his list of many firsts in dermatology, Dr. Goren was the first to develop a clinical genetic test for predicting androgenetic alopecia, the first to discover epigenetic markers predicting anti-androgen therapy response in female androgenetic alopecia, the first to develop a clinical acne vulgaris antibiotic response test based on P. Acnes bacterial genomics, and the first to develop a rapid-test for predicting Minoxidil response in Androgenetic Alopecia.

Dr. Goren is actively involved in the development, commercialization, and listing of several drugs and medical devices including new therapies for female pattern hair loss, chemotherapy-induced alopecia, excessive hair shedding, female sexual dysfunction, and COVID-19. His latest research involves the use of anti-androgen therapy for the treatment of COVID-19 that was performed in conjunction with the Brazilian Government.

Dr. Goren is the President and Chief Medical Officer of Applied Biology, Irvine, CA. He is External Medical Advisor and a Co-Researcher, Trichology Unit, Ramon y Cajal Hospital, Madrid, Spain, a Visiting Professor of Dermatology, Department of Dermatology and Venereology, Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, a Medical Doctor at the Skin & Cosmetic Research Dept., Shanghai Skin Disease Hospital, Shanghai, China, and a Visiting Medical Doctor, Department of Dermatology and Venereology, L.T.M. Medical College Sion, Mumbai, India. Clinical Research Director at Samel Hospital, Manaus, Brazil. Dr. Goren has published dozens of peer-reviewed original medical research papers. He is an honorary as well as an ordinary member of several dermatology societies worldwide as well as a regular lecturer at dermatology congresses around the world.

"We are delighted to welcome Dr. Goren to our Scientific Advisory Board" stated Dr. Glynn Wilson, Chief Scientific Officer of Jupiter Wellness. "We have already established an important collaboration with him and his colleagues for our clinical programs in eczema, burns, and actinic keratosis. Andy's expertise in dermatology and widespread access to clinics worldwide will help progress the development of our skin products and provide us access to patients through his many affiliations with large dermatological hospitals around the world. More importantly, he has a unique understanding of the translation of scientific data into commercial products".

About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ:JUPW) is a leading developer of skincare therapeutics and treatments. The Company's product pipeline of enhanced skincare therapeutics focuses on the endocannabinoid system to address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenue from a growing line of proprietary over-the-counter skincare products including CaniSun™ sunscreen and other wellness brands sold through www.cbdcaring.com.

For additional information, please visit www.jupiterwellness.com. The Company's public filings can be found at www.Sec.gov.

Safe Harbor Statement
To the extent, any statements contained in this presentation of Jupiter Wellness, Inc. (the "Company") contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 and the information that is based upon beliefs of, and information currently available to, the company's management as well as estimates and assumptions made by the company's management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words "estimate," "expect," intend," believe," plan," "anticipate," "projected" and other words or the negative of these terms and similar expressions as they relate to the company or the company's management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors relating to the company's industry, its operations and results of operations, and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Investor & Public Relations Contact Info
Phone: 561-244-7100
Email: info@JupiterWellness.com

SOURCE: Jupiter Wellness, Inc.



View source version on accesswire.com:
https://www.accesswire.com/655589/Jupiter-Wellness-Announces-Appointment-of-Dr-Andy-Goren-to-Scientific-Advisory-Board

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Clean Air Metals Drilling Confirms Down-Plunge Extension of the Escape Deposit20.10.2025 13:00:00 CEST | Press release

THUNDER BAY, ON / ACCESS Newswire / October 20, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSX.V:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to announce that its 2025 summer drilling program at the Company's 100%-owned Thunder Bay North Critical Minerals Project ("TBN") has confirmed the continuation of the Escape Deposit into a previously untested 2.5 km long magnetic anomaly that connects to the known mineral resources. The single hole completed during this program intersected high-tenor sulphide mineralization having comparable thickness and metal grades to the existing Escape Deposit resource. Given its significant size, the Escape down-plunge target represents the highest potential resource addition opportunity for the TBN project. Assay highlights from hole EL25-001: 53 m of 0.52 g/t Pt, 0.69 g/t Pd, 0.26% Cu and 0.17% Ni(from 404 m downhole, including 0.84 g/t Pt, 1.12 g/t Pd, 0.41% Cu and 021% Ni over 22 m from 411 m, and 1.08 g/t Pt, 1.41 g/t Pd, 0.52% Cu an

Innodata to Report Third Quarter 2025 Results16.10.2025 14:30:00 CEST | Press release

NEW YORK, NY, AL / ACCESS Newswire / October 16, 2025 / INNODATA INC. (Nasdaq:INOD) today announced that it will report Third Quarter 2025 results after the market closes on Thursday, November 6, 2025. A news release will be available in both the News and Investor Relations sections of the Innodata website, www.innodata.com. Innodata has scheduled an investor conference call for 5:00 PM Eastern time on that same day. The call-in numbers for the conference call are: (+1) 800 549 8228 North America (+44) 800 279 7040 United Kingdom (+1) 289 819 1520 International Participant Access Code 42719 # Investors are also invited to access a live Webcast of the conference call at the Investor Relations section of Innodata's website at https://investor.innodata.com/events-and-presentations/. Please note that the Webcast feature will be in listen-only mode. Call-in replay will be available for seven days following the conference call, and Webcast replay will be available for 30 days following the c

Karbon-X Corp. Reports Q1 2026 Revenue Growth and Strengthened Financial Position16.10.2025 14:00:00 CEST | Press release

Revenue reached $35.7 million, marking a 27,883% year-over-year increase driven by accelerated trading activity, and the continued expansion of Karbon-X's global carbon operations. CALGARY, AB / ACCESS Newswire / October 16, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or "the Company"), a vertically integrated climate solutions company, today announced financial results for the first quarter ended August 31, 2025, marking record revenue growth and continued execution of its strategic plan. The full filing is available under the Company's profile on OTC Markets at www.otcmarkets.com/stock/KARX/overview Karbon-X's Q1 2026 results underscore its accelerating growth trajectory and strong execution across all areas of its business. Q1 2026 Highlights Revenue Growth Karbon-X delivered transformational top-line growth as its carbon trading operations scaled globally. Revenue reached $35.7 million, up 27,883% year-over-year compared to $127,429 in Q1 2025. Growth was driven by the successfu

RelyEZ Unveils VentureEdge 800: Next-Generation 800 V AC Energy Storage System Tailored for Europe16.10.2025 08:20:00 CEST | Press release

BRUSSELS, BE / ACCESS Newswire / October 16, 2025 / RelyEZ Energy Storage proudly announces the launch of its latest innovation, VentureEdge 800, a next-generation 800 V AC battery energy storage system (BESS) designed to meet Europe's evolving grid requirements. The launch coincides with RelyEZ's participation as a Gold Sponsor at the Energy Storage Global Conference (ESGC 2025) in Brussels, underscoring its commitment to supporting the region's clean energy transition with cutting-edge, bankable storage technologies. A New Standard for European Grid Compatibility Across Europe, most PV and wind installations operate on 0.8 kV/15 kV transformer infrastructure, while conventional 0.4 kV PCS systems require additional step-up transformers - increasing cost, space, and energy loss. VentureEdge 800 eliminates this layer entirely, offering direct 800 V AC connectivity for seamless integration with existing assets. This forward-looking design translates into: 5-15 % CAPEX savings through re

Owkin Launches K Pro: The First Agentic AI Co-Pilot for Biopharma Powered by Biological Reasoning Models16.10.2025 07:00:00 CEST | Press release

Enterprise platform, queried through natural language, to help pharma, biotech, and investors make better decisions. High-quality biological patient data, enriched and integrated for use by AI agents. PARIS, FRANCE, GB / ACCESS Newswire / October 16, 2025 / Owkin today announces the launch of K Pro, its co-pilot bringing advanced agentic AI to biomedical research and drug development. K Pro helps pharmaceutical companies and biotechs make smarter decisions across the discovery and development pipeline, increase clinical success rates, and deliver decision-grade, data-driven biological insights fast enough to change program trajectories.Owkin K Pro Owkin K Pro - the Agentic AI Co-Pilot for Biopharma Built on a decade of Owkin's AI innovation and in close collaboration with leading academic and industry partners, K Pro is a scientist-first co-pilot, accessible to both researchers and executives. Through natural language interaction, users can ask complex biological questions and receive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye